Compare AANJANEYA LIFECARE with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS CIPLA DR. DATSONS LABS/
CIPLA
 
P/E (TTM) x -10.9 23.9 - View Chart
P/BV x 0.2 2.4 6.7% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 DR. DATSONS LABS   CIPLA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
CIPLA
Mar-19
DR. DATSONS LABS/
CIPLA
5-Yr Chart
Click to enlarge
High Rs126678 18.5%   
Low Rs31484 6.4%   
Sales per share (Unadj.) Rs133.0198.2 67.1%  
Earnings per share (Unadj.) Rs0.218.5 0.8%  
Cash flow per share (Unadj.) Rs6.635.0 18.9%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs128.8186.3 69.1%  
Shares outstanding (eoy) m31.66805.70 3.9%   
Bonus/Rights/Conversions FCCBESOP-  
Price / Sales ratio x0.62.9 20.1%   
Avg P/E ratio x516.131.4 1,645.8%  
P/CF ratio (eoy) x11.816.6 71.3%  
Price / Book Value ratio x0.63.1 19.5%  
Dividend payout %016.2 0.0%   
Avg Mkt Cap Rs m2,477468,031 0.5%   
No. of employees `000NA22.6 0.0%   
Total wages/salary Rs m5628,565 0.2%   
Avg. sales/employee Rs ThNM7,053.1-  
Avg. wages/employee Rs ThNM1,261.5-  
Avg. net profit/employee Rs ThNM659.1-  
INCOME DATA
Net Sales Rs m4,211159,710 2.6%  
Other income Rs m794,766 1.7%   
Total revenues Rs m4,289164,475 2.6%   
Gross profit Rs m56930,973 1.8%  
Depreciation Rs m20413,263 1.5%   
Interest Rs m4301,684 25.5%   
Profit before tax Rs m1320,791 0.1%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m65,695 0.1%   
Profit after tax Rs m514,924 0.0%  
Gross profit margin %13.519.4 69.6%  
Effective tax rate %48.027.4 175.3%   
Net profit margin %0.19.3 1.2%  
BALANCE SHEET DATA
Current assets Rs m6,852124,266 5.5%   
Current liabilities Rs m6,71137,715 17.8%   
Net working cap to sales %3.354.2 6.2%  
Current ratio x1.03.3 31.0%  
Inventory Days Days16191 177.5%  
Debtors Days Days31895 335.7%  
Net fixed assets Rs m3,673105,190 3.5%   
Share capital Rs m3171,611 19.6%   
"Free" reserves Rs m3,761148,511 2.5%   
Net worth Rs m4,078150,123 2.7%   
Long term debt Rs m1,67138,301 4.4%   
Total assets Rs m12,633239,633 5.3%  
Interest coverage x1.013.3 7.7%   
Debt to equity ratio x0.40.3 160.6%  
Sales to assets ratio x0.30.7 50.0%   
Return on assets %3.46.9 49.7%  
Return on equity %0.19.9 1.2%  
Return on capital %7.711.8 64.8%  
Exports to sales %22.934.7 66.0%   
Imports to sales %14.30-   
Exports (fob) Rs m96455,419 1.7%   
Imports (cif) Rs m602NA-   
Fx inflow Rs m96457,410 1.7%   
Fx outflow Rs m60719,041 3.2%   
Net fx Rs m35738,368 0.9%   
CASH FLOW
From Operations Rs m1,34516,911 8.0%  
From Investments Rs m-2,256-16,687 13.5%  
From Financial Activity Rs m-1,200-3,487 34.4%  
Net Cashflow Rs m-2,111-3,451 61.2%  

Share Holding

Indian Promoters % 4.5 16.0 28.3%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.0 12.2 -  
FIIs % 1.4 23.7 5.7%  
ADR/GDR % 0.0 1.1 -  
Free float % 94.1 26.2 359.2%  
Shareholders   20,807 161,166 12.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   ALEMBIC PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  ASTRAZENECA PHARMA  DIVIS LABORATORIES  

Compare DR. DATSONS LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

MSTC IPO: Should You Bet on This State-Run E-Commerce Player? (IPO)

Mar 13, 2019

Should you subscribe to the IPO of MSPC Limited?

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS - TTK HEALTHCARE COMPARISON

COMPARE DR. DATSONS LABS WITH

MARKET STATS